Alzheimer’s Disease Therapeutics Market
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that affects memory and other important mental function. Alzheimer’s disease is a lead cause of dementia in approximately 5.8 million Americans. At present, Alzheimer’s disease market faces an unmet need for disease-modifying therapy.
However, to fulfil the demand for a better treatments option in the market, several key players such as Eisai US, BioArctic, Biogen, Chugai Pharma USA, Anavex Life Sciences, Neurimmune, Neurotrope, vTv Therapeutics, AgeneBio, AZTherapies, Otsuka Pharmaceutical Companies, Novartis, Amgen, Roche, Cerecin, AbbVie, Araclon Biotech, Genentech, Lundbeck, and others are actively working towards the development of novel therapies for the Alzheimers Disease.
For more details, visit: Alzheimer’s Disease Therapeutics Market